Optimal molecular selection to benefit from nivolumab–ipilimumab in clear-cell renal cell carcinoma. Issue 7 (July 2022) - Vano, Yann-Alexandre; Elaidi, Réza; Phan, Letuan; Fridman, Wolf Herman; Sautès-Fridman, Catherine; Oudard, Stéphane; ,